LY 2228820-d9
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for complete information.
LY 2228820-d9 Product Information
LY 2228820-d9 is listed under Stable Isotopes and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-99013.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
LY 2228820-d9
CAT No.
CS-T-99013
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C26H28D9FN6O6S2
Molecular Weight
621.79
Category
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for complete information.
Description
Regulatory Description
LY 2228820-d9 is supplied with detailed characterization data compliant with regulatory guideline. LY 2228820-d9 can be used for analytical method development, method validation (AMV), Quality Control (QC), ANDA-related analytical work, and commercial pharmaceutical research applications.
Overview
"Laballed LY2228820, a novel and potent p38MAPK inhibitor with potent antiinflammatory activity. LY2228820 significantly inhibited phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, in both multiple myeloma (MM) cell lines and LT-BMSCs. LY2228820 is a potential candidate to improve MM patient outcome both by enhancing the effect of Bortezomib (B675700) and by reducing osteoskeletal events."
Synonyms
LY 2228820-d9
Application Notes
"Laballed LY2228820, a novel and potent p38MAPK inhibitor with potent antiinflammatory activity. LY2228820 significantly inhibited phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, in both multiple myeloma (MM) cell lines and LT-BMSCs. LY2228820 is a potential candidate to improve MM patient outcome both by enhancing the effect of Bortezomib (B675700) and by reducing osteoskeletal events."
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.